HC Wainwright restated their hold rating on shares of Mirna Therapeutics Inc. (NASDAQ:MIRN) in a report released on Tuesday.

Several other equities analysts have also recently weighed in on the company. Citigroup Inc. reduced their price target on Mirna Therapeutics from $4.50 to $2.00 and set a neutral rating for the company in a research report on Thursday, September 22nd. Leerink Swann restated a neutral rating and set a $1.50 target price (down from $4.00) on shares of Mirna Therapeutics in a research report on Wednesday, September 21st. Oppenheimer Holdings Inc. cut Mirna Therapeutics from an outperform rating to a market perform rating in a research report on Wednesday, September 21st. Cantor Fitzgerald cut Mirna Therapeutics from a buy rating to a hold rating and reduced their target price for the stock from $14.00 to $2.00 in a research report on Wednesday, September 21st. Finally, Zacks Investment Research upgraded Mirna Therapeutics from a hold rating to a buy rating and set a $2.75 target price for the company in a research report on Wednesday, September 7th. Six investment analysts have rated the stock with a hold rating, The company currently has an average rating of Hold and an average target price of $3.88.

Analyst Recommendations for Mirna Therapeutics (NASDAQ:MIRN)

Shares of Mirna Therapeutics (NASDAQ:MIRN) traded down 0.336% during trading on Tuesday, hitting $1.186. The stock had a trading volume of 32,092 shares. The company’s market capitalization is $24.71 million. The firm has a 50-day moving average price of $1.55 and a 200 day moving average price of $3.27. Mirna Therapeutics has a 52 week low of $1.12 and a 52 week high of $11.01.

About Mirna Therapeutics

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

5 Day Chart for NASDAQ:MIRN

Receive News & Stock Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related stocks with our FREE daily email newsletter.